Cell and Gene Therapy Market Surges with 22.6% CAGR Through 2032
The global cell and gene therapy market is experiencing significant growth, driven by technological advancements, increasing investment, and expanding applications in treating rare and chronic diseases. The market size is projected to grow from USD 10.7 billion in 2022 to USD 78.0 billion by 2032, with an impressive CAGR of 22.6% during the forecast period from 2022 to 2032. Key growth factors include the rising prevalence of genetic disorders and cancer, along with advancements in gene-editing technologies such as CRISPR.
Recent developments have further propelled market growth. Notably, Biogen and Ginkgo Bioworks completed a collaboration on AAV-based vectors, and Vertex Pharmaceuticals and CRISPR Therapeutics advanced their partnership for CTX001, targeting sickle cell disease and beta-thalassemia. Additionally, the U.S. FDA and European agencies have granted approvals for innovative therapies like bluebird bio’s Zynteglo for beta-thalassemia and Krystal Biotech’s VYJUVEK for dystrophic epidermolysis bullosa.
However, challenges persist, including high treatment costs, complex manufacturing processes, and stringent regulatory landscapes. The Inflation Reduction Act (IRA) and its impact on drug pricing add another layer of complexity, particularly for therapies designated as orphan drugs.
Overall, the cell and gene therapy market is poised for substantial growth, supported by continuous innovation, strategic collaborations, and increasing regulatory approvals.
Key Takeaways
- The market is projected to grow at a CAGR of 22.6%, reaching USD 78.0 billion by 2032 from USD 10.7 billion in 2022.
- Cell therapy holds a 54.3% market share, and gene therapy is revolutionizing medicine.
- Market growth is driven by increasing public and private investments, clinical pipeline expansion, and healthcare infrastructure improvements.
- High production costs, stringent regulations, and lengthy clinical study processes are key challenges to market growth.
- Oncological disorders were the prominent segment, with a 32% market share in 2022.
- Genetic disorders are expected to grow the fastest due to rising cases and government initiatives.
- Hospitals are predicted to register the highest CAGR during the forecast period.
- A notable trend is the growing global expenditure in R&D and innovative therapies.
- North America leads with a 49.6% market revenue share, while Europe shows significant growth driven by research and regulatory support.
- The Asia-Pacific region is expected to hold the maximum revenue share during the forecast period.
Get Sample PDF Report: https://market.us/report/cell-and-gene-therapy-market/request-sample/
Cell and Gene Therapy Market Key Segments
By Therapy Type
- Cell Therapy
- Gene Therapy
By Indication
- Genetic Disorders
- Cardiovascular Disorders
- Neurological Disorders
- Oncological Disorders
- Other Indications
By End-User
- Hospitals
- Academic & Research Institutes
- Cancer Care Centers
- Other End-Users
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=101909
Key Players Analysis
GlaxoSmithKline is advancing in the cell and gene therapy sector through strategic collaborations and innovative research. A notable partnership with Miltenyi Biotec aims to optimize the manufacture and delivery of cell and gene therapies, focusing on oncology and rare diseases. This collaboration leverages advanced processing technologies to enhance the efficiency and scalability of these therapies. Additionally, GSK’s five-year collaboration with Lyell Immunopharma targets the development of next-generation cancer cell therapies by improving T cell functionality and combating T cell exhaustion in solid tumors.
Novartis is a prominent player in the cell and gene therapy sector, primarily recognized for its CAR-T cell therapy, Kymriah, approved for treating certain types of blood cancers. The company continues to expand its portfolio by investing in innovative gene therapies for various indications, including ophthalmic and neuromuscular disorders. Novartis focuses on developing robust manufacturing capabilities and ensuring the accessibility of these advanced therapies globally. Their commitment to pioneering treatments in the cell and gene therapy space reflects their strategic emphasis on addressing unmet medical needs and improving patient outcomes.
Amgen is actively involved in the development of cell and gene therapies, particularly in the oncology field. The company’s approach includes leveraging its extensive expertise in biologics to create innovative treatments for cancer patients. Amgen’s pipeline features several promising candidates, including bispecific T cell engager (BiTE) therapies that direct the body’s immune system to target cancer cells. Through strategic partnerships and in-house research, Amgen aims to advance its cell and gene therapy portfolio, focusing on both solid tumors and hematologic malignancies to deliver transformative therapies to patients.
Bristol-Myers Squibb (BMS) is a key contributor to the cell and gene therapy landscape, focusing on immuno-oncology and hematologic malignancies. The acquisition of Celgene has significantly bolstered BMS’s capabilities, integrating cutting-edge CAR-T cell therapies like Breyanzi and Abecma into their portfolio. BMS continues to invest in research and development, aiming to enhance the efficacy and safety of cell-based treatments. The company’s strategic vision includes expanding the therapeutic potential of cell and gene therapies to address a broader range of diseases, ensuring comprehensive and innovative care for patients.
Spark Therapeutics, a subsidiary of Roche, is at the forefront of gene therapy innovation. Known for developing Luxturna, the first FDA-approved gene therapy for a genetic disease, Spark specializes in treatments for inherited retinal diseases and other genetic conditions. Their expertise in adeno-associated virus (AAV) vector technology underpins their robust pipeline, which includes therapies for hemophilia and neurodegenerative disorders. Spark’s focus on pioneering gene therapies aims to provide durable and potentially curative treatments, significantly improving the quality of life for patients with rare and debilitating diseases.
Cell and Gene Therapy Market Key Players:
- GalaxoSmithKline plc
- Novartis AG
- Amgen Inc.
- Bristol-Myers Squibb Company
- Spark Therapeutics
- Pfizer Inc.
- Biogen Inc.
- Thermo Fisher Scientific Inc.
- Other Key Players
Cell and Gene Therapy Market Report Scope >> Market Value (2023): USD 10.7 Billion || Forecast Revenue (2033): USD 78.0 Billion || CAGR (2024-2033): 22.6% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/cell-and-gene-therapy-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/
View More Trending Reports
White Biotechnology Market Projected To Reach USD 368.1 Bn By 2033, With CAGR Of 4.6%
Bandage Contact Lenses Market Projected to reach USD 8.4 Bn with 8.1% CAGR By 2033
Plastic Surgery Instruments Market Will Increase USD 3.6 Billion By 2033 with 9.1% CAGR
Sperm Function Testing Market Will Increase USD 1.8 Bn By 2033 with 5% CAGR By 2033
Editor Details
-
Company:
- Wired Release
- Website:
